| Ytd | -26.34% | |
| 1y | 182.05% |
| Open | 6.30 | Prev Close | 6.11 | Low | 6.21 | High | 6.62 | Mkt Cap | 2.29B |
| Vol | 5.08M | Avg Vol | 6.44M | EPS | -0.41 | P/E | -16.10 | Forward P/E | -96.83 |
| Beta | 1.53 | Short Ratio | 6.59 | Inst. Own | 64.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 5.59 | 200-d Avg | 5.71 | 1yr Est | 12.33 |
NUVB News
Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 mill
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Co
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key pati
Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirica
HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and ra
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest t
Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its
U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global onc
According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company f
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy
I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-dr
Nuvation Bio is upgraded to Buy, driven by Ibtrozi's growing adoption in ROS1+ NSCLC and improved mo
On Monday, 429 stocks made new 52-week lows.